IP Library Granted Patent US 10,973,853
Granted Patent B2
US 10,973,853 · App. 16/483,870 · Granted Apr 13, 2021

Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof

Inventors: Feifei Cui (Shanghai, CN); Lei Fang (Shanghai, CN); Bingshi Guo (Shanghai, CN); Zhengyi Wang (Shanghai, CN); Jingwu Zang (Shanghai, CN)
Assignee: I-Mab Biopharma US Limited
A61K35/17A61P31/18A61P35/00C07K16/2809A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,853
App. No.
16/483,870
Granted
Apr 13, 2021
Kind
B2
Abstract

The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.

Claims (7)

1. An antibody or fragment thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein, wherein the antibody or fragment thereof comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein the HCDR1 comprises the amino acid sequence of DYYMY (SEQ ID NO: 43), the HCDR2 comprises the amino acid sequence of SITKGGGSTYYPDTLKG (SEQ ID NO: 44), the HCDR3 comprises the amino acid sequence of QSSYDFVMDY (SEQ ID NO: 45), the LCDR1 comprises the amino acid sequence of KASQDVDTAVA (SEQ ID NO: 46), the LCDR2 comprises the amino acid sequence of WASARHT (SEQ ID NO: 47), and the LCDR3 comprises the amino acid sequence of QQYSNYPLT (SEQ ID NO: 48).

2. The antibody or fragment thereof of claim 1 , which is humanized and wherein the heavy chain variable region comprises one or more back mutations selected from the group consisting of 3K, 44R, and 82R, according to Kabat numbering, and combinations thereof.

3. The antibody or fragment thereof of claim 1 , which is humanized and wherein the light chain variable region comprises one or more back mutations selected from the group consisting of 3V, 42Q, 43S, and 87F, according to Kabat numbering, and combinations thereof.

4. The antibody or fragment thereof of claim 1 , comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27, and 49-52, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 27, and 49-52.

5. The antibody or fragment thereof of claim 1 , comprising a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 28, and 53-56, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 28, and 53-56.

6. The antibody or fragment thereof of claim 1 , which is bispecific.

7. An isolated cell comprising one or more polynucleotide encoding the antibody or fragment thereof of claim 1 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2021
From: I-MAB BIOPHARMA US LIMITED
To: I-MAB BIOPHARMA HONG KONG LIMITED
Reel/Frame 055994/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2021
From: I-MAB BIOPHARMA HONG KONG LIMITED
To: I-MAB BIOPHARMA (HANGZHOU) CO., LTD.
Reel/Frame 055994/0665 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: I-MAB
To: I-MAB BIOPHARMA US LIMITED
Reel/Frame 050723/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2019
From: FEIFEI CUI; LEI FANG; GUO, BINGSHI; WANG, ZHENGYI; ZANG, JINGWU
To: I-MAB
Reel/Frame 049984/0413 →
Priority Claims (1)
WO PCT/CN2018/075477 · Feb 6, 2018 · international
Continuity (1)
Related Publication 20210015858A1 · Jan 21, 2021